Diabetes

Treatments for Type 1 and Type 2 diabetes including GLP-1 agonists, insulin technologies, and glucose monitoring.

Companies

Pipeline Drugs

577

Key People

571

Diabetes Pipeline (577 drugs)

Commercial: 78Pre-clinical: 76Preclinical: 48Approved: 38Development: 29Phase 2: 27Approved/Commercial: 23Phase 1: 18Launched: 13Clinical: 11Early-stage Clinical: 11Phase 3: 9Phase III: 7Research: 6Not Applicable (Service Provider): 5Not Disclosed: 5R&D: 5Marketed (Global): 5Commercial Launch: 4Phase 1-3: 4Not Specified: 4Phase 2-4: 4preclinical: 4Regulatory Review: 4Exploratory: 3Discovery: 3Pre-clinical/Development: 3Phase 1/2: 3Development/Commercial: 3Pre-clinical/Research: 3Commercial Expansion: 3Proof of Concept: 3Research/Development: 3Service Platform: 3Commercial/Service: 3Phase I: 3Phase I/II: 3Clinical Investigation: 3Pre-Clinical: 3Commercial Development: 2Discovery/Development: 2Service: 2Research-Use Only: 2Service Offering: 2Phase 2a: 2Commercial Deployment: 2Clinical Trials: 2Commercial (licensed): 2Phase II: 2ANDA Approved: 2commercial: 2Commercial (Approved): 1ANDA Filed / Development: 1ANDA Pending / Development: 1Marketed / Line Extensions: 1FDA PMA Approved: 1CE Mark Approved: 1Research & Development: 1Development & Expansion: 1Assay Menu Expansion: 1Integrated Solution: 1Solution: 1Partnership: 1Development/Commercial (LDT): 1Commercial & Development: 1Commercial & Expansion: 1Development / Early Commercial: 1Phase I-IV: 1Not specified: 1Pre-clinical/Discovery: 1Commercial (Iterative Development): 1Regulatory: 1Investigational Device: 1Phase 2B: 1Commercial Enhancement: 1Development/Commercialization: 1Phase 2A: 1Phase 1B/2A: 1Phase 2b: 1Late-stage development: 1Preclinical or Early Clinical: 1Clinical Trials (phase unspecified): 1Phase 1b to Phase 4: 1NA (Service for all trial phases): 1Clinical Adoption: 1Clinical Research / Evidence Generation: 1Commercial Partnership & Development: 1Commercial & Program Expansion: 1Technology Development: 1Varies by Sponsor Protocol: 1Clinical Trial: 1Phase 1/1b: 1Phase IIb: 1Pre-clinical / Research: 1Research / Pre-clinical: 1Phase 1b: 1Clinical Research: 1NDA Filed: 1Preclinical/Phase I: 1Launched/Phase 3: 1Phase II/III: 1CE Mark / FDA Clearance (Ongoing): 1PMA Under Review: 1Commercial / Development: 1ANDA Tentative Approval: 1Process Validation: 1Continuous Development: 1Development/Regulatory: 1Pre-launch: 1Regulatory/Commercial: 1Registration & Launch: 1Development & Registration: 1Technology Transfer & Localization: 1Exploratory / Early Development: 1Commercial / Filed: 1Phase 4: 1Discovery/Preclinical: 1Launch Preparation: 1Pivotal: 1Service/Commercial: 1Marketed: 1

Drug	Company	Indication	Phase	Status
Luna Overnight Automated Insulin Delivery System	Luna Diabetes	Glycemic control in diabetes (for Multiple Daily Injection users)	Pre-clinical	Active
sCD146 CLIA Assay	YHLO Biotech	Biomarker (Cardiovascular/Kidney)	Commercial (Approved)	Launched
Blood Bank Panel	YHLO Biotech	Blood Screening	Commercial	IVDR CE Certified
Type 1 Diabetes Ecosystem	YHLO Biotech	Diabetes Diagnosis/Management	Commercial Development	Partnership (Sanofi)
iTLA mini Plus / iBC 900	YHLO Biotech	Laboratory Automation	Commercial	Launched
Authorized Generic of Nucynta® ER (tapentadol)	hikma	Pain Management	Launched	Launched (March 2026)
Authorized Generic of Nucynta® (tapentadol)	hikma	Pain Management	Launched	Launched (February 2026)
Complex Generic Injectables Portfolio	hikma	Various (Oncology Support, Anti-infectives, CNS)	ANDA Filed / Development	Active
Oral Solid Dose Generics Portfolio	hikma	Various (CV, CNS, Diabetes)	ANDA Pending / Development	Active
Branded Specialty Portfolio (MENA)	hikma	Oncology, Diabetes, Cardiovascular, Respiratory	Marketed / Line Extensions	Active
Undisclosed bLNP-Gene Therapy	BioGene Therapeutics	Diabetes (Type 1/2)	Preclinical	Research & Development
Next-Generation Pen Needle Platform	Embecta	Diabetes - Insulin Delivery	Development	Active R&D
Next-Generation Injection Device	Embecta	Diabetes - Insulin Delivery	Development	Active R&D
Digital Integration Initiatives	Embecta	Diabetes - Data Management & Adherence	Exploratory	Active Investigation
Eversense E3 / XL (180-day)	Senseonics	Continuous Glucose Monitoring for Diabetes	FDA PMA Approved	Commercial
Eversense 365-day System	Senseonics	Continuous Glucose Monitoring for Diabetes	CE Mark Approved	Commercial (Europe); Pre-submission (U.S.)
Next-Generation CGM System	Senseonics	Continuous Glucose Monitoring for Diabetes	Research & Development	Early-stage Development
DxC 500 AU Chemistry Analyzer	Beckman Coulter Diagnostics	Core Laboratory Chemistry Testing	Launched	Commercial
DxI 9000 Access Immunoassay Analyzer	Beckman Coulter Diagnostics	High-throughput Immunoassay Testing	Launched	Commercial
Digital Hematology Solutions	Beckman Coulter Diagnostics	Hematology / CBC Analysis	Development & Expansion	Active
Neurodegenerative Disease Assays (GFAP, NfL, pTau-217)	Beckman Coulter Diagnostics	Neurology / Alzheimer's Disease Research	Assay Menu Expansion	Active
Sepsis Host-Response & AMR Solutions	Beckman Coulter Diagnostics	Sepsis Diagnosis & Management	Integrated Solution	Commercial
Etiometry Clinical Intelligence Platform	Beckman Coulter Diagnostics	Critical Care / High-Acuity Patient Management	Commercial	Distributed
Advantaged Workflows	Beckman Coulter Diagnostics	Laboratory Operational Efficiency	Solution	Commercial
Generic Semaglutide Injection (Obeda)	Dr. Reddy's Laboratories	Type 2 Diabetes	Approved	Launched in India
Generic Semaglutide (Oral)	Dr. Reddy's Laboratories	Type 2 Diabetes, Obesity	Development	Targeted launch FY27
Bevacizumab Biosimilar	Dr. Reddy's Laboratories	Various Cancers	Approved	Launched in UK
Rituximab Biosimilar	Dr. Reddy's Laboratories	Non-Hodgkin Lymphoma, Rheumatoid Arthritis	Approved	Marketed Globally
Lenacapavir	Dr. Reddy's Laboratories	HIV-1 Infection	Approved	Commercialization in 120 countries via Gilead partnership
Toripalimab	Dr. Reddy's Laboratories	Recurrent/Metastatic Nasopharyngeal Carcinoma	Approved	Launched (India)
CAR T-Cell Therapy Program	Dr. Reddy's Laboratories	Relapsed/Refractory Multiple Myeloma	Development	Active
Injectable Contraceptive	Dr. Reddy's Laboratories	Women's Health / Family Planning	Development	Partnership with Gates Foundation
InStrong™	Lamark Biotech	Diabetes (Insulin)	Preclinical	Active
EyeStrong™	Lamark Biotech	Wet Age‑Related Macular Degeneration	Preclinical	Active
OncoStrong™	Lamark Biotech	Lung Cancer	Preclinical	Active
BioChaperone® Lispro (THDB0206)	Adocia	Type 1 Diabetes	Phase 3	Active
BioChaperone® Lispro	Adocia	Type 2 Diabetes	Phase 3	Active
BioChaperone® Combo (Insulin Glargine / Lixisenatide)	Adocia	Type 2 Diabetes	Phase 2	Active
BioChaperone® Glucagon	Adocia	Hypoglycemia	Phase 1	Active
AdOral® Insulin	Adocia	Diabetes	Preclinical	Platform Development
AdoShell® Islet Cell Therapy	Adocia	Type 1 Diabetes	Preclinical	Platform Development
AdoXLong Platform	Adocia	Diabetes & Obesity	Discovery	Platform Development
Insulin Aspart Biosimilar	USV Biologics Division	Diabetes Mellitus	Commercial	Active
Metformin API	USV Biologics Division	Type 2 Diabetes	Commercial	Active
Human Growth Hormone Biosimilar	USV Biologics Division	Growth Hormone Deficiency	Phase 2	Active
Monoclonal Antibody Biosimilar (Anti‑TNF)	USV Biologics Division	Rheumatoid Arthritis	Phase 1	Active
Woxheal	Centaur Pharmaceuticals	Diabetic foot ulcer	Phase 3	Active
Renadyl	Centaur Pharmaceuticals	Chronic kidney disease	Phase 2	Active
Control-IQ+ Algorithm Refinements	Tandem Diabetes	Type 1 & Type 2 Diabetes	Commercial	Ongoing Development
Tandem Mobi System Rollout	Tandem Diabetes	Type 1 & Type 2 Diabetes (U.S.)	Commercial Launch	Market Expansion